JP2023546561A5 - - Google Patents

Info

Publication number
JP2023546561A5
JP2023546561A5 JP2023521735A JP2023521735A JP2023546561A5 JP 2023546561 A5 JP2023546561 A5 JP 2023546561A5 JP 2023521735 A JP2023521735 A JP 2023521735A JP 2023521735 A JP2023521735 A JP 2023521735A JP 2023546561 A5 JP2023546561 A5 JP 2023546561A5
Authority
JP
Japan
Prior art keywords
peptide
binds
protein
chimera
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546561A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/054954 external-priority patent/WO2022081827A1/en
Publication of JP2023546561A publication Critical patent/JP2023546561A/ja
Publication of JP2023546561A5 publication Critical patent/JP2023546561A5/ja
Pending legal-status Critical Current

Links

JP2023521735A 2020-10-14 2021-10-14 ウイルスタンパク質および宿主タンパク質の分解のためのキメラコンジュゲートならびに使用方法 Pending JP2023546561A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091769P 2020-10-14 2020-10-14
US63/091,769 2020-10-14
PCT/US2021/054954 WO2022081827A1 (en) 2020-10-14 2021-10-14 Chimeric conjugates for degradation of viral and host proteins and methods of use

Publications (2)

Publication Number Publication Date
JP2023546561A JP2023546561A (ja) 2023-11-06
JP2023546561A5 true JP2023546561A5 (cg-RX-API-DMAC10.html) 2024-10-22

Family

ID=78709532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521735A Pending JP2023546561A (ja) 2020-10-14 2021-10-14 ウイルスタンパク質および宿主タンパク質の分解のためのキメラコンジュゲートならびに使用方法

Country Status (7)

Country Link
US (1) US20230330238A1 (cg-RX-API-DMAC10.html)
EP (1) EP4228699A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023546561A (cg-RX-API-DMAC10.html)
CN (1) CN116801908A (cg-RX-API-DMAC10.html)
AU (1) AU2021360898A1 (cg-RX-API-DMAC10.html)
CA (1) CA3193261A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022081827A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024003300A1 (en) * 2022-06-30 2024-01-04 Aptadegrad, S.L. Dna aptamer conjugates recognizing and degrading coronavirus proteins
GB202214796D0 (en) 2022-10-07 2022-11-23 Tocris Cookson Ltd Compounds
GB202214800D0 (en) 2022-10-07 2022-11-23 Tocris Cookson Ltd Compounds
WO2024086132A1 (en) * 2022-10-17 2024-04-25 Ohio University Protacs targeting viral enzymes for precise treatment of covid-19
CN121889401A (zh) * 2023-10-04 2026-04-17 丹娜-法伯癌症研究院 使用靶向蛋白质降解剂对mdm2扩增癌症进行选择性抑制
WO2025245225A1 (en) * 2024-05-22 2025-11-27 Dana-Farber Cancer Institute, Inc. Stapled peptide proteolysis targeting chimeras (sp-protacs) and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
ES2211033T3 (es) 1998-01-07 2004-07-01 Debio Recherche Pharmaceutique S.A. Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos.
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
BR0001870B1 (pt) 2000-05-29 2014-02-25 Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas
CN1187449C (zh) * 2003-06-05 2005-02-02 中国科学院上海药物研究所 可溶性sars病毒3cl蛋白酶的表达和纯化
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
WO2008106507A2 (en) 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
JP5788178B2 (ja) * 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
US8586707B2 (en) 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
US8524653B2 (en) 2008-09-22 2013-09-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010060112A1 (en) 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
EP3549951A3 (en) 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
EP3698811A1 (en) 2009-06-18 2020-08-26 Dana Farber Cancer Institute, Inc. Structured viral peptide compositions and methods of use
WO2011008260A2 (en) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US9297017B2 (en) 2010-06-08 2016-03-29 University Of Washington Methods and compositions for targeted protein degradation
AU2011314335A1 (en) * 2010-06-25 2013-01-31 Purdue Research Foundation Pathogen detection
EP2637680B1 (en) 2010-11-12 2017-03-01 Dana-Farber Cancer Institute, Inc. Cancer therapies
SG10201601840RA (en) 2011-09-09 2016-04-28 Agency Science Tech & Res P53 activating peptides
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
CA3113959A1 (en) 2012-09-26 2014-04-03 President And Fellows Of Harvard College Proline-locked stapled peptides and uses thereof
WO2014055039A1 (en) 2012-10-01 2014-04-10 Agency For Science, Technology And Research Peptides and methods for treating cancer
KR101616603B1 (ko) 2012-10-11 2016-04-28 서울대학교산학협력단 메틸 데그론 펩타이드 및 이를 이용한 단백질 수명 조절 방법
WO2014065760A1 (en) 2012-10-25 2014-05-01 Agency For Science, Technology And Research Methods for determining resistance against molecules targeting proteins
EP2912463A4 (en) 2012-10-25 2016-03-23 Agency Science Tech & Res PROCESS FOR DETERMINING THE RESISTANCE TO MOLECULES FOR THE TARGETING OF PROTEINS
US9115184B2 (en) 2013-03-01 2015-08-25 The Board Of Trustees Of The Leland Stanford Junior University Light-inducible system for regulating protein stability
JP2018503595A (ja) * 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. ペプチド模倣大環状分子およびその製剤
SG11201706562QA (en) 2015-02-13 2017-09-28 Agency Science Tech & Res NON-MEMBRANE DISRUPTIVE p53 ACTIVATING STAPLED PEPTIDES
US20190076504A1 (en) 2016-03-23 2019-03-14 Dana-Farber Cancer Institute, Inc. COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
WO2019133179A2 (en) * 2017-12-01 2019-07-04 Massachusetts Institute Of Technology Solution-phase affinity selection of inhibitors from combinatorial peptide libraries
CN120118207A (zh) 2017-12-15 2025-06-10 丹娜-法伯癌症研究院有限公司 稳定肽-介导的靶向蛋白降解
US11707452B2 (en) * 2018-08-20 2023-07-25 Arvinas Operations, Inc. Modulators of alpha-synuclein proteolysis and associated methods of use
CN110257357A (zh) * 2019-07-04 2019-09-20 中国人民解放军军事科学院军事医学研究院 MERS-CoV 3CLpro作为去泛素化酶和干扰素抑制剂的用途

Similar Documents

Publication Publication Date Title
Nelissen et al. Gelatinase B/matrix metalloproteinase‐9 cleaves interferon‐β and is a target for immunotherapy
KR101873773B1 (ko) 류마티즘 관절염 예방 또는 치료 조성물
Schellekens Factors influencing the immunogenicity of therapeutic proteins
RU2355700C9 (ru) Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита с
Zawacka‐Pankau et al. Pharmacological reactivation of p53 as a strategy to treat cancer
BR0112666A (pt) Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c
DE69334266D1 (de) Therapeutische Zusammensetzungen aus Antikorper und Antisens Nukleinsäuren gegen Serrate
JP2021506814A5 (cg-RX-API-DMAC10.html)
RU95115239A (ru) Аналог эритропоэтина
EP1322338A4 (en) COMPOSITIONS AND METHODS FOR USE OF THE CAPSID PROTEIN FROM FLAVIVIRES OR PESTVIRUSES
HUP0003384A2 (hu) Legalább egy, kettős szálú RNS és legalább egy, vírus elleni szer kombinációját tartalmazó termék
WO2002008256A3 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
BR0212897A (pt) Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos
BRPI0307276B8 (pt) uso de um peptídio para prevenção e/ou tratamento de esclerose múltipla
JP2006506942A5 (cg-RX-API-DMAC10.html)
US20230330238A1 (en) Chimeric conjugates for degradation of viral and host proteins and methods of use
JP2023542453A5 (cg-RX-API-DMAC10.html)
KR20230008867A (ko) 백신 항원으로서의 코로나바이러스 스파이크 단백질의 조작, 이의 설계 및 용도
DK0661999T3 (da) Vacciner mod felint immundefekt virus (FIV)
ES2171086T3 (es) Uso de proteinas hmg para la preparacion de medicamentos con actividad citotoxica.
KR20090016671A (ko) 레플리킨 펩티드 및 이의 용도
KR970701724A (ko) 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin)
CA2354153A1 (en) Compounds and methods for modulating activation of nf-.kappa.b
Minagar et al. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF
EP2196211A1 (en) Apolactoferrin compositions and methods of the use thereof for treating viral hepatitis c